Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Event Logistics

- PMLiVE

AZ moves closer to EU approval for ovarian cancer drug

Olaparib on course to be first PARP inhibitor available for ovarian cancer

- PMLiVE

ECC 2013: Nintedanib data boosts Boehringer’s oncology ambitions

Lung cancer drug shows extended overall survival in adenocarcinoma patients

- PMLiVE

Pfizer’s Brandicourt joins Bayer Healthcare as CEO

He replaces acting chief executive Wolfgang Plischke

New CEO for Merck Serono

Belén Garijo replaces Stefan Oschmann, who moves into a wider group role

- PMLiVE

inVentiv Health boosts London digital team

Appoints Emma D’Arcy as head of participatory medicine

National Institute for Health and Care Excellence NICE logo

NICE to update ovarian cancer drug guidelines

Draft guidance backs paclitaxel and Janssen’s Caelyx but not gemcitabine, topetecan or trabectedin

- PMLiVE

Novartis tops leaderboard at PM Society Digital Media Awards

Secures four wins for two separate campaigns

- PMLiVE

Research into meningococcal B disease

The first approved vaccine represents a major success for meningococcal B research efforts

- PMLiVE

Accelerating drug development by harnessing technology

The pressure is on for biopharma to radically improve the drug development model

- PMLiVE

EASD 2013: Novo Nordisk’s diabetes combination IDegLira impresses in study

Mix of Tresiba and Victoza helps 81 per cent achieve blood sugar target in phase III

- PMLiVE

Mixed news for Lilly on cancer hope ramucirumab

Fails in phase III for breast cancer but better results for stomach cancer

Keith Webber leaves FDA for Perrigo

Switches regulatory agency for biopharma company

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links